Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23841163 | 0.86 | RAB9A (0.41) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL11890370 | 0.84 | RAB9A (0.54) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL19864588 | 0.82 | RAB9A (0.43) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL11890375 | 0.81 | RAB9A (0.58) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL8241745 | 0.79 | EPHX1 (0.58) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL18199497 | 0.77 | RAB9A (0.49) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL5067337 | 0.77 | RAB9A (0.49) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL18199502 | 0.77 | RAB9A (0.41) | RAB9AHPGDCYP3A4CYP2C19EPHX1 | |
| SCHEMBL23826543 | 0.75 | BTK (0.47) | RAB9ACYP3A4EPHX1KMT2ABTK | |
| SCHEMBL23826924 | 0.75 | BTK (0.47) | RAB9ACYP3A4EPHX1KMT2ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-07-18 | — | — | US | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | RAB9A 4668/4885HPGD 4203/4885CYP3A4 2758/4885 |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | SCN9A, SCN7A, SCN8A | RAB9A 434/4885HPGD 4694/4885CYP3A4 4222/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | RAB9A 409/4885HPGD 4549/4885CYP3A4 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.